Cited by 524

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

The integrated landscape of driver genomic alterations in glioblastoma

Frattini, Veronique, Trifonov, Vladimir, Chan, Joseph Minhow, Castano, Angelica, Lia, Marie, Abate, Francesco, Keir, Stephen T, Ji, Alan X, Zoppoli, Pietro, Niola, Francesco, Danussi, Carla, Dolgalev, Igor, Porrati, Paola, Pellegatta, Serena, Heguy, Adriana, Gupta, Gaurav, Pisapia, David J, Canoll, Peter, Bruce, Jeffrey N, McLendon, Roger E, Yan, Hai, Aldape, Ken, Finocchiaro, Gaetano, Mikkelsen, Tom, Privé, Gilbert G, Bigner, Darell D, Lasorella, Anna, Rabadan, Raul, Iavarone, Antonio·2013·Nature Genetics

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/ng.2734

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 56

  1. Porter, K.R., McCarthy, B.J., Freels, S., Kim, Y. & Davis, F.G. Prevalence estimates for primary brain tumors in the United States by age, gender, behavior, and histology. Neuro. Oncol. 12, 520–527 (2010). · DOI
  2. Noushmehr, H. et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17, 510–522 (2010). · DOI · Paper page
  3. Bass, A.J. et al. Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. Nat. Genet. 43, 964–968 (2011). · DOI
  4. Chinnaiyan, A.M. & Palanisamy, N. Chromosomal aberrations in solid tumors. Prog. Mol. Biol. Transl. Sci. 95, 55–94 (2010). · DOI
  5. Singh, D. et al. Transforming fusions of FGFR and TACC genes in human glioblastoma. Science 337, 1231–1235 (2012). · DOI
  6. Rubin, A.F. & Green, P. Mutation patterns in cancer genomes. Proc. Natl. Acad. Sci. USA 106, 21766–21770 (2009). · DOI · Paper page
  7. Fan, Z. et al. BCOR regulates mesenchymal stem cell function by epigenetic mechanisms. Nat. Cell Biol. 11, 1002–1009 (2009). · DOI
  8. Wamstad, J.A. & Bardwell, V.J. Characterization of Bcor expression in mouse development. Gene Expr. Patterns 7, 550–557 (2007). · DOI
  9. Wamstad, J.A., Corcoran, C.M., Keating, A.M. & Bardwell, V.J. Role of the transcriptional corepressor Bcor in embryonic stem cell differentiation and early embryonic development. PLoS ONE 3, e2814 (2008). · DOI
  10. Pugh, T.J. et al. Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature 488, 106–110 (2012). · DOI · Paper page
  11. Zhang, J. et al. A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature 481, 329–334 (2012). · DOI
  12. Beroukhim, R. et al. The landscape of somatic copy-number alteration across human cancers. Nature 463, 899–905 (2010). · DOI · Paper page
  13. Kantarci, S. et al. Mutations in LRP2, which encodes the multiligand receptor megalin, cause Donnai-Barrow and facio-oculo-acoustico-renal syndromes. Nat. Genet. 39, 957–959 (2007). · DOI
  14. Willnow, T.E. et al. Defective forebrain development in mice lacking gp330/megalin. Proc. Natl. Acad. Sci. USA 93, 8460–8464 (1996). · DOI
  15. Christ, A. et al. LRP2 is an auxiliary SHH receptor required to condition the forebrain ventral midline for inductive signals. Dev. Cell 22, 268–278 (2012). · DOI
  16. Cowin, P.A. et al. LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin. Cancer Res. 72, 4060–4073 (2012). · DOI
  17. Lima, F.R. et al. Glioblastoma: therapeutic challenges, what lies ahead. Biochim. Biophys. Acta 1826, 338–349 (2012).
  18. Bekker-Jensen, S. et al. HERC2 coordinates ubiquitin-dependent assembly of DNA repair factors on damaged chromosomes. Nat. Cell Biol. 12, 80–86 (2010). · DOI
  19. Harlalka, G.V. et al. Mutation of HERC2 causes developmental delay with Angelman-like features. J. Med. Genet. 50, 65–73 (2013). · DOI
  20. Nacak, T.G., Leptien, K., Fellner, D., Augustin, H.G. & Kroll, J. The BTB-kelch protein LZTR-1 is a novel Golgi protein that is degraded upon induction of apoptosis. J. Biol. Chem. 281, 5065–5071 (2006). · DOI
  21. Errington, W.J. et al. Adaptor protein self-assembly drives the control of a cullin-RING ubiquitin ligase. Structure 20, 1141–1153 (2012). · DOI
  22. Ji, A.X. & Prive, G.G. Crystal structure of KLHL3 in complex with Cullin3. PLoS ONE 8, e60445 (2013). · DOI
  23. Boyden, L.M. et al. Mutations in kelch-like 3 and cullin 3 cause hypertension and electrolyte abnormalities. Nature 482, 98–102 (2012). · DOI
  24. Louis-Dit-Picard, H. et al. KLHL3 mutations cause familial hyperkalemic hypertension by impairing ion transport in the distal nephron. Nat. Genet. 44, 456–460 (2012). · DOI
  25. Emanuele, M.J. et al. Global identification of modular cullin-RING ligase substrates. Cell 147, 459–474 (2011). · DOI
  26. Galan, J.M. & Peter, M. Ubiquitin-dependent degradation of multiple F-box proteins by an autocatalytic mechanism. Proc. Natl. Acad. Sci. USA 96, 9124–9129 (1999). · DOI
  27. Zhang, D.D. et al. Ubiquitination of Keap1, a BTB-Kelch substrate adaptor protein for Cul3, targets Keap1 for degradation by a proteasome-independent pathway. J. Biol. Chem. 280, 30091–30099 (2005). · DOI
  28. Günther, H.S. et al. Glioblastoma-derived stem cell–enriched cultures form distinct subgroups according to molecular and phenotypic criteria. Oncogene 27, 2897–2909 (2008). · DOI
  29. Abu-Elneel, K. et al. A δ-catenin signaling pathway leading to dendritic protrusions. J. Biol. Chem. 283, 32781–32791 (2008). · DOI
  30. Arikkath, J. et al. δ-catenin regulates spine and synapse morphogenesis and function in hippocampal neurons during development. J. Neurosci. 29, 5435–5442 (2009). · DOI
  31. Kosik, K.S., Donahue, C.P., Israely, I., Liu, X. & Ochiishi, T. δ-catenin at the synaptic-adherens junction. Trends Cell Biol. 15, 172–178 (2005). · DOI
  32. Israely, I. et al. Deletion of the neuron-specific protein δ-catenin leads to severe cognitive and synaptic dysfunction. Curr. Biol. 14, 1657–1663 (2004). · DOI
  33. Jun, G. et al. δ-catenin is genetically and biologically associated with cortical cataract and future Alzheimer-related structural and functional brain changes. PLoS ONE 7, e43728 (2012). · DOI
  34. Hicks, S., Wheeler, D.A., Plon, S.E. & Kimmel, M. Prediction of missense mutation functionality depends on both the algorithm and sequence alignment employed. Hum. Mutat. 32, 661–668 (2011). · DOI · Paper page
  35. Phillips, H.S. et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9, 157–173 (2006). · DOI
  36. Carro, M.S. et al. The transcriptional network for mesenchymal transformation of brain tumours. Nature 463, 318–325 (2010). · DOI
  37. Pierotti, M.A. & Greco, A. Oncogenic rearrangements of the NTRK1/NGF receptor. Cancer Lett. 232, 90–98 (2006). · DOI
  38. Dunn, G.P. et al. Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev. 26, 756–784 (2012). · DOI
  39. Liu, C. et al. Chemokine receptor CXCR3 promotes growth of glioma. Carcinogenesis 32, 129–137 (2011). · DOI
  40. Vivanco, I. et al. Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov. 2, 458–471 (2012). · DOI
  41. Forbes, S.A. et al. COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer. Nucleic Acids Res. 38, D652–D657 (2010). · DOI
  42. Northcott, P.A. et al. Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature 488, 49–56 (2012). · DOI
  43. Tiacci, E. et al. BRAF mutations in hairy-cell leukemia. N. Engl. J. Med. 364, 2305–2315 (2011). · DOI
  44. Iyer, M.K., Chinnaiyan, A.M. & Maher, C.A. ChimeraScan: a tool for identifying chimeric transcription in sequencing data. Bioinformatics 27, 2903–2904 (2011). · DOI
  45. Vilella, A.J. et al. EnsemblCompara GeneTrees: complete, duplication-aware phylogenetic trees in vertebrates. Genome Res. 19, 327–335 (2009). · DOI · Paper page
  46. Seal, R.L., Gordon, S.M., Lush, M.J., Wright, M.W. & Bruford, E.A. genenames.org : the HGNC resources in 2011. Nucleic Acids Res. 39, D514–D519 (2011). · DOI
  47. Danecek, P. et al. The variant call format and VCFtools. Bioinformatics 27, 2156–2158 (2011). · DOI
  48. Söding, J. Protein homology detection by HMM-HMM comparison. Bioinformatics 21, 951–960 (2005). · DOI
  49. Roy, A., Kucukural, A. & Zhang, Y. I-TASSER: a unified platform for automated protein structure and function prediction. Nat. Protoc. 5, 725–738 (2010). · DOI
  50. Fülop, V. & Jones, D.T. Beta propellers: structural rigidity and functional diversity. Curr. Opin. Struct. Biol. 9, 715–721 (1999). · DOI
  51. Tropepe, V. et al. Distinct neural stem cells proliferate in response to EGF and FGF in the developing mouse telencephalon. Dev. Biol. 208, 166–188 (1999). · DOI
  52. Niola, F. et al. Id proteins synchronize stemness and anchorage to the niche of neural stem cells. Nat. Cell Biol. 14, 477–487 (2012). · DOI
  53. Niola, F. et al. Mesenchymal high-grade glioma is maintained by the ID-RAP1 axis. J. Clin. Invest. 123, 405–417 (2013). · DOI
  54. Zhao, X. et al. The N-Myc-DLL3 cascade is suppressed by the ubiquitin ligase Huwe1 to inhibit proliferation and promote neurogenesis in the developing brain. Dev. Cell 17, 210–221 (2009). · DOI
  55. Zhao, X. et al. The HECT-domain ubiquitin ligase Huwe1 controls neural differentiation and proliferation by destabilizing the N-Myc oncoprotein. Nat. Cell Biol. 10, 643–653 (2008). · DOI
  56. Friedman, H.S. et al. Experimental chemotherapy of human medulloblastoma cell lines and transplantable xenografts with bifunctional alkylating agents. Cancer Res. 48, 4189–4195 (1988).

Cited by

Sorted by citations

See all 524

Metadata

Authors
Frattini, V., Trifonov, V., Chan, J. M., Castano, A., Lia, M., Abate, F., Keir, S. T., Ji, A. X., Zoppoli, P., Niola, F., Danussi, C., Dolgalev, I., Porrati, P., Pellegatta, S., Heguy, A., Gupta, G., Pisapia, D. J., Canoll, P., Bruce, J. N., McLendon, R. E., Yan, H., Aldape, K., Finocchiaro, G., Mikkelsen, T., Privé, G. G., Bigner, D. D., Lasorella, A., Rabadan, R., & Iavarone, A.
Venue
Nature Genetics
Published
2013-08-05
Volume
45
Issue
10
Pages
1141-1149
ISSN
  • 1061-4036
  • 1546-1718
Cited by
524
References
9
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review